Editas Medicine, Inc.: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Nov 12, 2019 and accepted by EDGAR at Nov 12, 2019, 16:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-07-01 to 2019-09-30 | $3.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2019-01-01 to 2019-09-30 | $8.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2019-07-01 to 2019-09-30 | $22.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-30 | $62.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | −$34.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | −$101.5m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-07-01 to 2019-09-30 | −$32.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | −$96.0m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | −$81.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-30 | $4.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-09-30 | $104.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $339.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $372.4m | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $66.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $162.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-09-30 | $210.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-19-010798. Last ingested by Listed: Nov 6, 2026, 17:42 ET. Listed shows no prices and gives no investment advice.